Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Peroxide chain reaction characterized by initiation, propagation and termination. (RH: PUFA; R·: free radical; ROO·: peroxide; ROOH: hydroxyl peroxide; AH: vitamin E; A·: oxidized Vitamin E. Adapted from: Tappel AL. Vitamin E and free radical peroxidation of lipids. Annals of the New York Academy of Sciences. 1972; 203(1):12‐28.
Figuras y tablas -
Figure 1

Peroxide chain reaction characterized by initiation, propagation and termination. (RH: PUFA; R·: free radical; ROO·: peroxide; ROOH: hydroxyl peroxide; AH: vitamin E; A·: oxidized Vitamin E. Adapted from: Tappel AL. Vitamin E and free radical peroxidation of lipids. Annals of the New York Academy of Sciences. 1972; 203(1):12‐28.

Ir a la figura de la revisiónAbrir en una pestaña nueva

PRISMA flow diagram showing process of study selection
Figuras y tablas -
Figure 2

PRISMA flow diagram showing process of study selection

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Risk of bias summary: review authors' judgements about each methodological domain for each included study.
Figuras y tablas -
Figure 4

Risk of bias summary: review authors' judgements about each methodological domain for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 1 Lung function FEV1 [% pred].
Figuras y tablas -
Analysis 1.1

Comparison 1 Antioxidants versus control, Outcome 1 Lung function FEV1 [% pred].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 2 Lung function FVC [% pred].
Figuras y tablas -
Analysis 1.2

Comparison 1 Antioxidants versus control, Outcome 2 Lung function FVC [% pred].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 3 Quality of life: Quality of Well Being Scale.
Figuras y tablas -
Analysis 1.3

Comparison 1 Antioxidants versus control, Outcome 3 Quality of life: Quality of Well Being Scale.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 4 Oxidative stress: Lipid peroxidation (H2O2) [μmol/L].
Figuras y tablas -
Analysis 1.4

Comparison 1 Antioxidants versus control, Outcome 4 Oxidative stress: Lipid peroxidation (H2O2) [μmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 5 Oxidative stress: Lipid peroxidation (TBARS) [μmol/L].
Figuras y tablas -
Analysis 1.5

Comparison 1 Antioxidants versus control, Outcome 5 Oxidative stress: Lipid peroxidation (TBARS) [μmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 6 Oxidative stress: Lipid peroxidation (F2‐isoprostanes) [ng/L].
Figuras y tablas -
Analysis 1.6

Comparison 1 Antioxidants versus control, Outcome 6 Oxidative stress: Lipid peroxidation (F2‐isoprostanes) [ng/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 7 Oxidative stress: Enzyme function ‐ GPX [U/g Hb].
Figuras y tablas -
Analysis 1.7

Comparison 1 Antioxidants versus control, Outcome 7 Oxidative stress: Enzyme function ‐ GPX [U/g Hb].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 8 Oxidative stress: Enzyme function ‐ SOD [U/mg Hb].
Figuras y tablas -
Analysis 1.8

Comparison 1 Antioxidants versus control, Outcome 8 Oxidative stress: Enzyme function ‐ SOD [U/mg Hb].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 9 Oxidative stress: Potency (TEAC) [mmol/L].
Figuras y tablas -
Analysis 1.9

Comparison 1 Antioxidants versus control, Outcome 9 Oxidative stress: Potency (TEAC) [mmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 10 Plasma antioxidant status ‐ vitamin E [μmol/L].
Figuras y tablas -
Analysis 1.10

Comparison 1 Antioxidants versus control, Outcome 10 Plasma antioxidant status ‐ vitamin E [μmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 11 Plasma antioxidant status ‐ β‐carotene [μmol/L].
Figuras y tablas -
Analysis 1.11

Comparison 1 Antioxidants versus control, Outcome 11 Plasma antioxidant status ‐ β‐carotene [μmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 12 Plasma antioxidant status ‐ selenium [μmol/L].
Figuras y tablas -
Analysis 1.12

Comparison 1 Antioxidants versus control, Outcome 12 Plasma antioxidant status ‐ selenium [μmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 13 Plasma antioxidant status ‐ vitamin C [μmol/L].
Figuras y tablas -
Analysis 1.13

Comparison 1 Antioxidants versus control, Outcome 13 Plasma antioxidant status ‐ vitamin C [μmol/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 14 Inflammation: plasma fatty acid status [mg/L].
Figuras y tablas -
Analysis 1.14

Comparison 1 Antioxidants versus control, Outcome 14 Inflammation: plasma fatty acid status [mg/L].

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Antioxidants versus control, Outcome 15 Antiobiotic days per patient.
Figuras y tablas -
Analysis 1.15

Comparison 1 Antioxidants versus control, Outcome 15 Antiobiotic days per patient.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Antioxidants versus control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Lung function FEV1 [% pred] Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

1.1 At 2 months (combined supplement)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

1.2 At 6 months (ß‐carotene)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

2 Lung function FVC [% pred] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

2.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 Quality of life: Quality of Well Being Scale Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

3.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Oxidative stress: Lipid peroxidation (H2O2) [μmol/L] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

4.1 At 5 months (selenium)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

5 Oxidative stress: Lipid peroxidation (TBARS) [μmol/L] Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Totals not selected

6 Oxidative stress: Lipid peroxidation (F2‐isoprostanes) [ng/L] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

6.1 At 2 months (combined supplementation)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Oxidative stress: Enzyme function ‐ GPX [U/g Hb] Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

7.1 At 2 months (combined supplementation)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

7.2 At 5 months (selenium)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

8 Oxidative stress: Enzyme function ‐ SOD [U/mg Hb] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

8.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

9 Oxidative stress: Potency (TEAC) [mmol/L] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

9.1 At 6 months (ß‐carotene)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Plasma antioxidant status ‐ vitamin E [μmol/L] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

10.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11 Plasma antioxidant status ‐ β‐carotene [μmol/L] Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

11.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

11.2 At 6 months (ß‐carotene)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

12 Plasma antioxidant status ‐ selenium [μmol/L] Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

12.1 At 2 months (combined supplement)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

12.2 At 5 months (selenium)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

13 Plasma antioxidant status ‐ vitamin C [μmol/L] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

13.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

14 Inflammation: plasma fatty acid status [mg/L] Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

14.1 At 2 months (combined supplement)

1

Mean Difference (IV, Fixed, 95% CI)

0.0 [0.0, 0.0]

15 Antiobiotic days per patient Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Totals not selected

15.1 At 2 months (combined supplement)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

15.2 At 6 months (ß‐carotene)

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 1. Antioxidants versus control
Ir a la tabla de la revisión